

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Remifentanil Hydrochloride for Injection Product Name:

Manufacturer Name: Fresenius Kabi USA, LLC Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300 Customer Service Phone (888) 386-1300

Number:

Health Issues Information: (800) 551-7176 SDS Creation Date: May 01, 2013 June 10, 2015 SDS Revision Date:

SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:

Signal Word: WARNING

GHS Class: Specific Target Organ Toxicity - STOT, Single Exposure SE. Category 3.

Hazard Statements: May cause respiratory irritation.

Avoid breathing dust/fume/gas/mist/vapours/spray. Precautionary Statements:

Use only outdoors or in a well-ventilated area.

IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.

Call a POISON CENTER or doctor/physician if you feel unwell.

Store in a well-ventilated place. Keep container tightly closed.

Store locked up.
Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Avoid contact with Emergency Overview:

skin, eves, nostrils and mouth.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Eye: Contact with eyes may cause irritation.

May cause irritation. Inhalation: May cause irritation.

Ingestion: May be harmful if ingested.

Aggravation of Pre-Existing

Conditions

Inhalation:

None generally recognized.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Remifentanil HCI	132539-07-2	1, 2, and 5 mg/vial	
Glycine	56-40-6	15 mg/vial	
Hydrochloric Acid	7647-01-0	As needed to adjust pH	

SECTION 4: FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of

the eyes by separating the eyelids with fingers. Get immediate medical attention.

 $Immediately \ wash \ skin \ with \ plenty \ of soap \ and \ water for 15 to 20 \ minutes, \ while \ removing contaminated \ clothing \ and \ shoes. \ Get \ medical \ attention \ if \ irritation \ develops \ or \ persists.$ Skin Contact:

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.

Ingestion: If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established Flash Point Method: Not established. Auto Ignition Temperature: Not established. Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established.

Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to Fire Fighting Instructions: minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding

environment.

As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear. Protective Equipment:

Hazardous Combustion Byproducts:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of

combustion.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Evacuate area and keep unnecessary and unprotected personnel from entering the spill area Personal Precautions:

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue. Methods for cleanup:

SECTION 7: HANDLING and STORAGE

Handling: When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes.

Use with adequate ventilation. Use only in accordance with directions.

Store between 2 to 25°C (36 to 77°F). Storage:

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

shower.

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

General ventilation is sufficient if this product is being used in a controlled medical setting (clinic **Engineering Controls:**

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Chemical splash goggles. Wear a face shield also when splash hazard exist. Eye/Face Protection:

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection:

No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

Hydrochloric Acid:

Guideline ACGIH: TLV-STEL: 2 ppm(ceiling)

Guideline OSHA: OSHA PEL-STEL 5 ppm Ceiling/Peak

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: Lyophilized powder. Color: White to off-white. Boiling Point: Not established. Melting Point: Not established. Solubility: Soluble. in water. Vapor Density: Not established. Vapor Pressure: Not established.

2.5-3.5 (reconstituted.) pH:

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established.

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Not established.

Hazardous Polymerization: Not reported.

Avoid contact with oxidizing agents. Incompatible Materials:

SECTION 11: TOXICOLOGICAL INFORMATION

Remifentanil HCl:

Percent Volatile:

TN2413670 RTECS Number:

Other Toxicological Information: Intravenous. - Monkey TDLo: 0.001 mg/kg [Behavioral - Changes in psychophysiological tests] Subcutaneous - Amphibian frog TDLo: 2931661 ug/kg [Behavioral - Analgesia]

Hydrochloric Acid:

RTECS Number: MW4025000

Eye: Eye - Rabbit Total particulate/dust (T): 5 mg/30S (RTECS)

Administration onto the skin - Human Standard Draize test.: 4 %/24H (RTECS)

Inhalation: Inhalation - Rat LC50: 3124 ppm/1H [Sense Organs and Special Senses (Olfaction) - effect, not

Otherwise specified Sense Organs and Special Senses (Eye) - Iritis]
Inhalation - Mouse LC50: 1108 ppm/1H [Sense Organs and Special Senses (Eye) - effect, not

Otherwise specified Lungs, Thorax, or Respiration - Respiratory stimulation Skin and Appendages - Dermatitis, other (After systemic exposure)]
Inhalation - Rat LC50: 45000 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Mouse LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - LC50: 0.1 gm/m3 [Details of toxic effects not reported other than lethal dose value]
Inhalation - Rat LC50: 60938 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Mouse LC50: 20487 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50: 7004 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Mouse LC50: 3940 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50: 3700 ppm/30M [Details of toxic effects not reported other than lethal dose

value] Inhalation - Mo value] (RTECS) Mouse LC50: 2644 ppm/30M [Details of toxic effects not reported other than lethal dose

Ingestion: Oral - Rabbit LD50: 900 mg/kg [Details of toxic effects not reported other than lethal dose value]

(RTECS)

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Medicine, solid, toxic, n.o.s.

UN3249 DOT UN Number: DOT Hazard Class: 6.1 DOT Packing Group:

DOT Exemption: ORM-D Consumer Commodity.

Quantities equal to or less than 0.25 kg per inner packaging are not subject to the full packaging and

labelling requirements

SECTION 15: REGULATORY INFORMATION

Glycine:

TSCA Inventory Status: Listed 200-711-8 EINECS Number: Canada DSL: Listed

Hydrochloric Acid:

TSCA Inventory Status: Listed EINECS Number: 231-595-7

SARA: EPCRA - 40 CFR Part 372 - (SARA Title III) Section 313 Listed Chemical.

Section 302 EHS:

EPCRA (SARA Title III) Section 302 (40 CFR Part 355) Extremely Hazardous Substances (EHS) Threshold Planning Quantity (TPQ) in pounds.: 500 Lbs.

Section 304 RQ: EPCRA (SARA Title III) Section 304 Extremely Hazardous Substances (EHS) Reportable Quantities (RQ)

in pounds.: 5,000 Lbs.

Canada DSL:

Canada IDL: $Identified\ under\ the\ Canadian\ Hazardous\ Products\ Act\ Ingredient\ Disclosure\ List:\ 0.1\%.845(502)$

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 3 HMIS Fire Hazard: 1 HMIS Reactivity: 1 HMIS Personal Protection: Χ

SDS Creation Date: May 01, 2013 SDS Revision Date: June 10, 2015

The information contained herein pertains to this material. It is the responsibility of each individual Disclaimer:

party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.